In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...